NanoViricides, Inc. — Form 10-Q Summary
Business context and reporting period
Development-stage nanobiopharmaceutical company; fiscal second quarter and six-month period ended December 31, 2011. The company had no commercialized products or revenue and was focused on preclinical antiviral drug development under licenses from related party TheraCour Pharma. Financial statements are unaudited.
Financial performance and position
| Metric | Three months ended Dec. 31, 2011 | Six months ended Dec. 31, 2011 | Comparable 2010 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development | $1.011 million | $1.670 million | $1.872 million for six months |
| General and administrative | $326,000 | $788,000 | $738,000 for six months |
| Total operating expenses | $1.337 million | $2.458 million | $2.610 million for six months |
| Net loss | $1.391 million | $2.531 million | $2.673 million for six months |
| Basic and diluted loss per share | $0.009 | $0.017 | $0.02 for six months |
- Six-month R&D expense declined about 11% year over year; G&A increased about 7%. Total operating expense fell about 6%, and net loss narrowed about 5%.
- Cash and cash equivalents were $12.099 million at December 31, 2011, versus $9.224 million at June 30, 2011. Total current assets were $12.422 million; current liabilities were $1.173 million; working capital was approximately $11.249 million.
- Six-month operating cash use was $1.902 million, compared with $2.448 million in 2010. Investing cash use was $47,000; financing provided $4.825 million, principally from Series B preferred stock issuance. Cash increased $2.875 million over the six months.
- Total assets were $13.561 million and stockholders’ equity was $12.388 million at December 31. The company reported no long-term debt; current liabilities included a $159,000 derivative liability and $736,000 payable to related parties.
- Accumulated development-stage deficit was $25.748 million. Common shares outstanding were 149.766 million at December 31 and 151.484 million as of February 8, 2012.
Material changes, outlook, and risks
- Seaside 88, LP bought $2.5 million of Series B preferred stock in November 2011; a further $2.5 million purchase closed February 8, 2012. The preferred securities convert automatically into common shares at formula-based prices linked to trading prices, creating potential dilution. The filing reports a $0.656 conversion price at the February closing and estimated offering expenses of about $180,000.
- Management stated that cash and the subsequent financing would support operations through at least December 31, 2013 at the then-current expenditure rate. The filing also anticipates needing an additional $10–15 million to advance a candidate through clinical-trial phases; inability to obtain financing could significantly delay plans.
- Management’s estimated 18-month spending plan was $6.7 million for R&D, $1.25 million for corporate overhead, $2.0 million for capital costs, and $2.0 million for staffing. Estimates are uncertain; management noted limited drug-development experience and that further studies could increase costs and extend timelines.
- The company had filed a pre-IND meeting application for influenza candidate NV-INF-1 and submitted briefing documents to the FDA in January 2012. Management described promising influenza and HIV animal-study results, but emphasized that studies were preliminary and indicative, not confirmatory. No detailed FDA-ready toxicology package had been completed; clinical safety and efficacy remain unproven.
- Management reported lead or active preclinical programs in influenza, HIV, eye infections, herpes, dengue, rabies, and Ebola/Marburg. These are development claims, not approved therapies or established commercial prospects.
- TheraCour is affiliated through common control by the company’s president and chairman and owns approximately 24.9% of the company’s common stock. TheraCour received $862,000 in development costs for the six months; the license terms also provide for cost-based fees, a monthly lab-supply charge, and a 15% royalty on future net sales. The company’s primary animal-study vendor, KARD Scientific, is affiliated with its consulting chief regulatory officer.
- A lawsuit by a former legal-services provider seeks $77,601 in fees; the company denies the claim, has counterclaimed, and recorded no accrual. A separate shareholder action seeks inspection of company books and records; the company moved to dismiss and recorded no accrual.
- Management identified a material weakness in internal control over financial reporting: no independent directors and no audit committee chaired by an independent financial expert. It concluded internal control over financial reporting was not effective at December 31, 2011, while disclosure controls were deemed effective.
Important facts for investors to verify
- Cash balance and runway assumptions, including the filing’s separate MD&A reference to $12.093 million rather than the balance-sheet and cash-flow figure of $12.099 million.
- Series B preferred-stock conversion terms, subsequent issuance proceeds, and resulting actual and potential common-share dilution.
- Progress, costs, and timing for FDA-enabling toxicology, manufacturing, and IND work, particularly for NV-INF-1; reported efficacy is preclinical.
- Related-party development charges, license economics, and oversight of TheraCour and affiliated service providers.
- Status and potential outcome of the legal proceedings and remediation of the disclosed internal-control material weakness.